Citations

Showing 10 of 108135 citations.

Genetics, Genomics, and Precision Medicine
Meschia, James F. , Dichgans, Martin , Dichgans, Martin , Meschia, James F

Mayo Clinic

Stroke | September 2, 2021 | Volume: 52 | Issue: 10 | Pages: 3385-3387

10.1161/strokeaha.121.033966 | PMID 34470485 Get It

Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis
Eaton, John E. , Rupp, Christian , Eusebi, Leonardo Henry , Munster, Kim van, Voitl, Robert, Thorburn, Douglas , Ponsioen, Cyriel Y. , Petersen, Bret T. , Baron, Todd H. , Gostout, Christopher J., Levy, Michael J. , Martin, John A. , Dierkhising, Ross , Kamath, Patrick S. , Topazian, Mark , Haseeb, Abdul, Enders, Felicity T, Martin, John, Haseeb, Abdul , Munster, Kim N. van , Enders, Felicity , Petersen, Bret T. , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Levy, Michael J. , Storm, Andrew C. , Gores, Gregory J.

Mayo Clinic

Hepatology Communications | September 2, 2021 | Volume: 6 | Issue: 4 | Pages: 809-820

10.1002/hep4.1813 | PMID 34558848 Get It

The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial. To identify predictors of jaundice resolution after ERCP and whether resolution is associated with improved patient outcomes, we conducted a retrospective cohort study of 124 patients with jaundice and PSC. These patients underwent endoscopic biliary balloon dilation and/or stent placement at an American tertiary center, with validation in a separate cohort of 102 patients from European centers. Jaundice resolved after ERCP in 52% of patients. Median follow‐up was 4.8 years. Independent predictors of jaundice resolution included older age (P = 0.048; odds ratio [OR], 1.03 for every 1‐year increase), shorter duration of jaundice (P = 0.059; OR, 0.59 for every 1‐year increase), lower Mayo Risk Score (MRS) (P = 0.025; OR, 0.58 for every 1‐point increase), and extrahepatic location of the most advanced biliary stricture (P = 0.011; OR, 3.13). A logistic regression model predicted jaundice resolution with area under the receiver operator characteristic curve of 0.67 (95% confidence interval, 0.5‐0.79) in the validation set. Independent predictors of death or transplant during follow‐up included higher MRS at the time of ERCP (P < 0.0001; hazard ratio [HR], 2.33 for every 1‐point increase), lower total serum bilirubin before ERCP (P = 0.031; HR, 0.91 for every 1 mg/dL increase), and persistence of jaundice after endoscopic therapy (P = 0.003; HR, 2.30). Conclusion: Resolution of jaundice after endoscopic treatment of biliary strictures is associated with longer transplant‐free survival of patients with PSC. The likelihood of resolution is affected by demographic, hepatic, and biliary variables and can be predicted using noninvasive data. These findings may refine the use of ERCP in patients with jaundice with PSC.
Ligaments and muscles stabilizing the radio-ulno-carpal joint
García‐Elías, Marc , Ananos, Dirck , Esplugas, Mireia , Hagert, Elisabet , Heras-Palou, Carlos , Kakar, Sanjeev

Mayo Clinic

Journal of Hand Surgery (European Volume) | September 2, 2021 | Volume: 47 | Issue: 1 | Pages: 65-72

10.1177/17531934211042316 | PMID 34472392 Get It

The technical simplicity of the Darrach procedure may explain why it has been so popular. Excising the distal ulna, however, may have potentially undesired consequences to the biomechanics in two areas: the distal radioulnar and the ulno-carpal joints. These conjointly define the radio-ulno-carpal joint (RUCJ). The RUCJ is not a small and irrelevant articulation that can be removed without possibly paying a functional penalty. It is an important link of the antebrachial frame that provides stability to the distal forearm and the carpus. This article revisits the mechanisms by which some ligaments and muscles ensure that all forces about and within the RUCJ are dealt with efficiently.
Risk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study
Kwon, Jung Hyun , Wi, Chung‐Il , Seol, Hee Yun , Park, Miguel , King, Katherine S. , Ryu, Euijung , Sohn, Sunghwan , Liu, Hongfang , Juhn, Young J. , King, Katherine , Kwon, Jung Hyun , Sohn, Sunghwan , Liu, Hongfang , Wi, Chung-Ii

Mayo Clinic

Allergy, Asthma & Immunology Research | September 2, 2021 | Volume: 13 | Issue: 5 | Pages: 697

10.4168/aair.2021.13.5.697 | PMID 34486256 Get It

Bridging Intention and Action for Employee Well-Being Using the Intentional Action (InAct) Process: Workshop-Lecture Series
McLeod, Heidi , Salinas, Manisha , Schafer, Julie L, Ventenilla, Joseph, Dabrh, Abd Moain Abu , Perlman, Adam I, Salinas, Manisha G, Abu Dabrh, Abd Moain , Perlman, Adam

Mayo Clinic

Global Advances in Health and Medicine | September 1, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/21649561211015653 | PMID 34497736 Get It

Background Employee wellness programs can help manage stress and alleviate burnout. Objective To pilot and disseminate the Intentional Action(InAct) concept for employee wellbeing. Methods Five independent interactive workshop-lectures with an automated audience response system. Descriptive analysis of participant response data. Results Participants (n = 275): rated spirituality, physical environment and nutrition the most highly in contributing to their present well-being. Ninety-eight percent (n = 269) of participants identified a focus area to work on. The well-being area most selected was Exercise, (35% n = 95), however, other non-traditional areas, including Personal and Professional Development (18% n = 48), Relationships and Communication (17% n = 47), were selected, along with mind-body connection and mindful awareness (6% n = 15 and n = 16). Conclusion The pilot engaged employees to reflect and set goals for their future well-being. Healthcare institutions implementing programs should consider a broad range of whole person strategies addressing employee well-being, which go beyond the traditional focus on exercise and nutrition.
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Costa, Luciano J. , Monohan, Gregory, Kovacsovics, Tibor , Burwick, Nicholas , Kaufman, Jonathan L. , Hong, Wan‐Jen , Dail, Monique , Masud, Abdullah Al , Munasinghe, Wijith, Ross, Jeremy A. , Bueno, Orlando F. , Kumar, Shaji , Stadtmauer, Edward A. , Kaufman, Jonathan L , Dail, Monique , Kumar, Shaji K , Costa, Luciano J , Davies, Faith E. , Jakubowiak, Andrzej , Salem, Ahmed Hamed , Yang, Xiaoqing

Mayo Clinic

Blood Advances | September 1, 2021 | Volume: 5 | Issue: 19 | Pages: 3748-3759

10.1182/bloodadvances.2020004146 | PMID 34470049 Get It

Abstract Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis of MM cells, and its efficacy may be potentiated through combination with agents that increase BCL-2 dependency or have complementary mechanisms of action. The safety, tolerability, pharmacokinetics, and antitumor activity of venetoclax in combination with carfilzomib and dexamethasone (VenKd) in adults with relapsed/refractory MM (RRMM) were investigated in this phase 2 dose-escalation study. Oral venetoclax (400 or 800 mg) was administered daily in combination with intravenous carfilzomib (27, 56, or 70 mg/m2) and oral dexamethasone (20 or 40 mg) in 4 dose-finding cohorts. The expansion cohort received venetoclax 800 mg, carfilzomib 70 mg/m2, and dexamethasone 40 mg. Forty-nine patients received treatment. Median prior lines of therapy was 1 (range, 1-3), and median time in the study was 27 months. The most common treatment-emergent adverse events were diarrhea (65%), fatigue (47%), nausea (47%), and lymphopenia (35%). Serious adverse events occurred in 26 (53%) patients. Of 3 treatment-emergent deaths, 1 was considered treatment related. The overall response rate was 80% in all patients, 92% in patients with t(11;14) (n = 13), and 75% in patients without (n = 36). The rate of complete response or better was 41%. Median progression-free survival was 22.8 months. Treatment with VenKd was well tolerated and showed promising response rates in this RRMM patient population, with greater responses observed in patients with t(11;14). This trial is registered at www.clinicaltrials.gov as #NCT02899052.
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma
Fleming, Jessica L. , Pugh, Stephanie L. , Fisher, Barbara J., Lesser, Glenn J. , Macdonald, David R., Bell, Erica H. , McElroy, Joseph , Becker, Aline Paixão , Timmers, Cynthia , Aldape, Kenneth , Rogers, Leland , Doyle, Thomas J. , Werner‐Wasik, Maria, Bahary, Jean-Paul , Tsai, Ya-Yu , D’Souza, David , Sneed, Penny K. , Kwok, Young , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

JCO Precision Oncology | September 1, 2021 | Volume: No volume available | Issue: 5 | Pages: 1397-1407

10.1200/po.21.00112 | PMID 34589661 Get It

PURPOSE This study sought to determine the prognostic significance of the WHO-defined glioma molecular subgroups along with additional alterations, including MGMT promoter methylation and mutations in ATRX, CIC, FUBP1, TERT, and TP53, in NRG/RTOG 0424 using long-term follow-up data. METHODS Mutations were determined using an Ion Torrent sequencing panel. 1p/19q co-deletion and MGMT promoter methylation were determined by Affymetrix OncoScan and Illumina 450K arrays. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and tested using the log-rank test. Hazard ratios were calculated using the Cox proportional hazard model. Multivariable analyses (MVAs) included patient pretreatment characteristics. RESULTS We obtained complete molecular data to categorize 80/129 eligible patients within the WHO subgroups. Of these, 26 (32.5%) were IDHmutant/co-deleted, 28 (35%) were IDHmutant/non-co-deleted, and 26 (32.5%) were IDHwild-type. Upon single-marker MVA, both IDHmutant subgroups were associated with significantly better OS and PFS ( P values < .001), compared with the IDHwild-type subgroup. MGMT promoter methylation was obtained on 76 patients, where 58 (76%) were methylated and 18 (24%) were unmethylated. Single-marker MVAs demonstrated that MGMT promoter methylation was statistically significant for OS ( P value < .001) and PFS ( P value = .003). In a multimarker MVA, one WHO subgroup comparison ( IDHmutant/co-deleted v IDHwild-type) was significant for OS ( P value = .045), whereas MGMT methylation did not retain significance. CONCLUSION This study reports the long-term prognostic effect of the WHO molecular subgroups, MGMT promoter methylation, and other mutations in NRG/RTOG 0424. These results demonstrate that the WHO molecular classification and MGMT both serve as strong prognostic indicators, but that MGMT does not appear to add statistically significant prognostic value to the WHO subgrouping, above and beyond IDH and 1p/19q status.
Chronic Meningitis
Aksamit, Allen J.

Mayo Clinic

New England Journal of Medicine | September 1, 2021 | Volume: 385 | Issue: 10 | Pages: 930-936

10.1056/nejmra2032996 | PMID 34469648 Get It

A Picture Is Worth a Thousand Words: RadioGraphics Visual Abstracts for Quick Learning
Carnahan, Molly B. , Segaran, Nicole , Vilanilam, George K. , Tomblinson, Courtney M. , Segaran, Nicole L , Vilanilam, George , Harrison, Molly

Mayo Clinic

RadioGraphics | September 1, 2021 | Volume: 41 | Issue: 5 | Pages: E145-E146

10.1148/rg.2021210166 | PMID 34469216 Get It